

# Schwalbe Ec, Schwalbe E

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/2965158/schwalbe-ec-schwalbe-e-publications-by-year.pdf>  
**Version:** 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.  
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

28 papers	877 citations	13 h-index	29 g-index
32 ext. papers	1,248 ext. citations	7.4 avg, IF	3.68 L-index

#	Paper	IF	Citations
28	MEDB-71. Molecular characterisation of group 4 medulloblastoma improves risk-stratification and its biological understanding. <i>Neuro-Oncology</i> , <b>2022</b> , 24, i123-i123	1	
27	MEDB-43. Development of a bioinformatics pipeline for identification of differential DNA methylation events associated with medulloblastoma relapse. <i>Neuro-Oncology</i> , <b>2022</b> , 24, i115-i115	1	
26	MEDB-65. Molecular subclassification of a national cohort of pediatric medulloblastoma based on methylation profile. <i>Neuro-Oncology</i> , <b>2022</b> , 24, i121-i121	1	
25	Human Bone Proteomes before and after Decomposition: Investigating the Effects of Biological Variation and Taphonomic Alteration on Bone Protein Profiles and the Implications for Forensic Proteomics. <i>Journal of Proteome Research</i> , <b>2021</b> , 20, 2533-2546	5.6	4
24	Advanced molecular pathology for rare tumours: A national feasibility study and model for centralised medulloblastoma diagnostics. <i>Neuropathology and Applied Neurobiology</i> , <b>2021</b> , 47, 736-747	5.2	3
23	Emergence and maintenance of actionable genetic drivers at medulloblastoma relapse. <i>Neuro-Oncology</i> , <b>2021</b> ,	1	3
22	Inter and intra-tumoral heterogeneity as a platform for personalized therapies in medulloblastoma. <i>Pharmacology &amp; Therapeutics</i> , <b>2021</b> , 228, 107828	13.9	2
21	Integration of genome-level data to allow identification of subtype-specific vulnerability genes as novel therapeutic targets. <i>Oncogene</i> , <b>2021</b> , 40, 5213-5223	9.2	1
20	Time, pattern, and outcome of medulloblastoma relapse and their association with tumour biology at diagnosis and therapy: a multicentre cohort study. <i>The Lancet Child and Adolescent Health</i> , <b>2020</b> , 4, 865-874	14.5	12
19	Pediatric pan-central nervous system tumor analysis of immune-cell infiltration identifies correlates of antitumor immunity. <i>Nature Communications</i> , <b>2020</b> , 11, 4324	17.4	32
18	Challenges of starting treatment protocols for acute lymphoblastic leukaemia in a low-income setting - the Blantyre experience. <i>British Journal of Haematology</i> , <b>2020</b> , 191, e87-e90	4.5	1
17	Second-generation molecular subgrouping of medulloblastoma: an international meta-analysis of Group 3 and Group 4 subtypes. <i>Acta Neuropathologica</i> , <b>2019</b> , 138, 309-326	14.3	90
16	SH2B3 inactivation through CN-LOH 12q is uniquely associated with B-cell precursor ALL with iAMP21 or other chromosome 21 gain. <i>Leukemia</i> , <b>2019</b> , 33, 1881-1894	10.7	14
15	Imaging Characteristics of Wingless Pathway Subgroup Medulloblastomas: Results from the German HIT/SIOP-Trial Cohort. <i>American Journal of Neuroradiology</i> , <b>2019</b> , 40, 1811-1817	4.4	5
14	MBCL-31. A WHOLE CHROMOSOME ABERRATION PHENOTYPE IN NON-WNT/NON-SHH TUMORS PREDICTS OUTCOME WITHIN STANDARD-RISK MEDULLOBLASTOMAS FROM THE HIT-SIOP-PNET4 CLINICAL TRIAL. <i>Neuro-Oncology</i> , <b>2018</b> , 20, i123-i123	1	78
13	ATRT-20. INTRA- AND EXTRA-CRANIAL MALIGNANT RHABDOID TUMOURS SHARE COMMON LOCATION-INDEPENDENT CLINICAL AND MOLECULAR DISEASE CHARACTERISTICS. <i>Neuro-Oncology</i> , <b>2018</b> , 20, i31-i32	1	78
12	Response: Commentary: Reducing Viability Bias in Analysis of Gut Microbiota in Preterm Infants at Risk of NEC and Sepsis. <i>Frontiers in Cellular and Infection Microbiology</i> , <b>2018</b> , 8, 374	5.9	1

11	Prognostic effect of whole chromosomal aberration signatures in standard-risk, non-WNT/non-SHH medulloblastoma: a retrospective, molecular analysis of the HIT-SIOP PNET 4 trial. <i>Lancet Oncology, The</i> , <b>2018</b> , 19, 1602-1616	21.7	33
10	A chromatographic approach to distinguish Gram-positive from Gram-negative bacteria using exogenous volatile organic compound metabolites. <i>Journal of Chromatography A</i> , <b>2017</b> , 1501, 79-88	4.5	13
9	Novel molecular subgroups for clinical classification and outcome prediction in childhood medulloblastoma: a cohort study. <i>Lancet Oncology, The</i> , <b>2017</b> , 18, 958-971	21.7	248
8	The Treatment of Possible Severe Infection in Infants: An Open Randomized Safety Trial of Parenteral Benzylpenicillin and Gentamicin Versus Ceftriaxone in Infants. <i>Pediatric Infectious Disease Journal</i> , <b>2017</b> , 36, e328-e333	3.4	7
7	Genomic analysis of endemic clones of toxigenic and non-toxigenic <i>Corynebacterium diphtheriae</i> in Belarus during and after the major epidemic in 1990s. <i>BMC Genomics</i> , <b>2017</b> , 18, 873	4.5	19
6	Analysis of <i>Listeria</i> using exogenous volatile organic compound metabolites and their detection by static headspace-multi-capillary column-gas chromatography-ion mobility spectrometry (SHS-MCC-GC-IMS). <i>Analytical and Bioanalytical Chemistry</i> , <b>2017</b> , 409, 4247-4256	4.4	18
5	Reducing Viability Bias in Analysis of Gut Microbiota in Preterm Infants at Risk of NEC and Sepsis. <i>Frontiers in Cellular and Infection Microbiology</i> , <b>2017</b> , 7, 237	5.9	29
4	Next-generation systematics: An innovative approach to resolve the structure of complex prokaryotic taxa. <i>Scientific Reports</i> , <b>2016</b> , 6, 38392	4.9	72
3	Epigenetic landscape correlates with genetic subtype but does not predict outcome in childhood acute lymphoblastic leukemia. <i>Epigenetics</i> , <b>2015</b> , 10, 717-26	5.7	17
2	DNA methylation profiling of medulloblastoma allows robust subclassification and improved outcome prediction using formalin-fixed biopsies. <i>Acta Neuropathologica</i> , <b>2013</b> , 125, 359-71	14.3	95
1	The Effects of Inter-Individual Biological Differences and Taphonomic Alteration on Human Bone Protein Profiles: Implications for the Development of PMI/AAD Estimation Methods		2